Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
30,284,111
-
Total 13F shares
-
10,926,163
-
Share change
-
+10,916,163
-
Total reported value
-
$409,790,602
-
Price per share
-
$37.51
-
Number of holders
-
51
-
Value change
-
+$409,462,563
-
Number of buys
-
50
Institutional Holders of Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) as of Q2 2020
As of 30 Jun 2020,
Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) was held by
51 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
10,926,163 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., ORBIMED ADVISORS LLC, Foresite Capital Management IV, LLC, FMR LLC, VR Adviser, LLC, BlackRock Inc., CHI Advisors LLC, Logos Global Management LP, VANGUARD GROUP INC, and Invesco Ltd..
This page lists
51
institutional shareholders reporting positions in this security
for the Q2 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.